Three Boston-area biotechs are awaiting drug approval decisions from the U.S. Food and Drug Administration before the end of 2025.

The deadlines set by the U.S. Food and Drug Administration to approve or reject drugs are known as PDUFA dates, for the Prescription Drug User Fee Act. Those deadlines for the three local companies involve approving new drugs or expanding the use of certain medicines made by Agios Pharmaceuticals, Aldeyra Therapeutics and Rhythm Pharmaceuticals.

Stream NBC10 Boston news for free, 24/7, wherever you are. WATCH HERE

More on this story from Boston Business Journal

See Full Page